CoChat

Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer

Open access
Yi, Joo Mi, Dhir, Mashaal, Van Neste, Leander, Downing, Stephanie R., Jeschke, Jana, Glöckner, Sabine C., de Freitas Calmon, Marilia, Hooker, Craig M., Funes, Juan M., Boshoff, Chris, Smits, Kim M., van Engeland, Manon, Weijenberg, Matty P., Iacobuzio-Donahue, Christine A., Herman, James G., Schuebel, Kornel E., Baylin, Stephen B., Ahuja, Nita · 2011 · Clinical Cancer Research
Cited by 146

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: The importance of genetic and epigenetic alterations maybe in their aggregate role in altering core pathways in tumorigenesis. Experimental Design: Merging genome-wide genomic and epigenomic alterations, we identify key genes and pathways altered in colorectal cancers (CRC). DNA methylation analysis was tested for predicting survival in CRC patients using Cox proportional hazard model. Results: We identified 29 low frequency-mutated genes that are also inactivated by epigenetic mechanisms in CRC. Pathway analysis showed the extracellular matrix (ECM) remodeling pathway is silenced in CRC. Six ECM pathway genes were tested for their prognostic potential in large CRC cohorts (n = 777). DNA methylation of IGFBP3 and EVL predicted for poor survival (IGFBP3: HR = 2.58, 95% CI: 1.37–4.87, P = 0.004; EVL: HR = 2.48, 95% CI: 1.07–5.74, P = 0.034) and simultaneous methylation of multiple genes predicted significantly worse survival (HR = 8.61, 95% CI: 2.16–34.36, P < 0.001 for methylation of IGFBP3, EVL, CD109, and FLNC). DNA methylation of IGFBP3 and EVL was validated as a prognostic marker in an independent contemporary-matched cohort (IGFBP3 HR = 2.06, 95% CI: 1.04–4.09, P = 0.038; EVL HR = 2.23, 95% CI: 1.00–5.0, P = 0.05) and EVL DNA methylation remained significant in a secondary historical validation cohort (HR = 1.41, 95% CI: 1.05–1.89, P = 0.022). Moreover, DNA methylation of selected ECM genes helps to stratify the high-risk stage 2 colon cancers patients who would benefit from adjuvant chemotherapy (HR: 5.85, 95% CI: 2.03–16.83, P = 0.001 for simultaneous methylation of IGFBP3, EVL, and CD109). Conclusions: CRC that have silenced genes in ECM pathway components show worse survival suggesting that our finding provides novel prognostic biomarkers for CRC and reflects the high importance of integrative analyses linking genetic and epigenetic abnormalities with pathway disruption in cancer. Clin Cancer Res; 17(6); 1535–45. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-2509

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 146

Metadata

Authors
Yi, J. M., Dhir, M., Van Neste, L., Downing, S. R., Jeschke, J., Glöckner, S. C., de Freitas Calmon, M., Hooker, C. M., Funes, J. M., Boshoff, C., Smits, K. M., van Engeland, M., Weijenberg, M. P., Iacobuzio-Donahue, C. A., Herman, J. G., Schuebel, K. E., Baylin, S. B., & Ahuja, N.
Venue
Clinical Cancer Research
Published
2011-03-15
Volume
17
Issue
6
Pages
1535-1545
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2051705329
Cited by
146
References
5
FWCI
6.47
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-2509
The paper
Yi, J. M., Dhir, M., Van Neste, L., Downing, S. R., Jeschke, J., Glöckner, S. C., de Freitas Calmon, M., Hooker, C. M., Funes, J. M., Boshoff, C., Smits, K. M., van Engeland, M., Weijenberg, M. P., Iacobuzio-Donahue, C. A., Herman, J. G., Schuebel, K. E., Baylin, S. B., & Ahuja, N. (2011). Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-2509

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.